Applied DNA Sciences, Inc. (NASDAQ:APDN) (the “Company”), a leader in polymerase chain reaction (“PCR”)-based technologies, announced that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC (“ADCL”), has initiated analytical validation of a Company-developed, PCR-based monkeypox virus test that is specific for the genetic signature of the monkeypox virus. The test has been developed as a type of NYSDOH Laboratory Developed Test (“LDT”). If the test is validated by ADCL, a validation package will be submitted to New York State Department of Health (“NYSDOH”) for approval. If approved, the test will be used to power ADCL’s monkeypox testing services.
Cowen & Co. Downgrades Avantor to Market Perform, Lowers Price Target to $28
Cowen & Co. analyst Dan Brennan downgrades Avantor (NYSE:AVTR) from Outperform to Market Perform and lowers the price target from $39 to $28.